Use of liver breath tests to assess severity of nonalcoholic fatty liver disease

Reviews on Recent Clinical Trials

Volumn 9, Issue 3, 2014, Pages 178-184

  Furnari, Manuele ^a   Savarino, Vincenzo ^a   Giannini, Edoardo G ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

Aminopyrine; Cirrhosis; Galactose; Prognosis; Staging; Steatohepatitis; Steatosis

Indexed keywords

BIOCHEMICAL MARKER; CARBON 13;

13C ALPHA KETOISOCAPROIC ACID BREATH TEST; 13C AMINOPYRINE BREATH TEST; 13C CAFFEINE BREATH TEST; 13C METHACETIN BREATH TEST; 13C METHIONINE BREATH TEST; ARTICLE; BREATH ANALYSIS; CLINICAL EVALUATION; CLINICAL PRACTICE; CORRELATIONAL STUDY; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; DISEASE SEVERITY ASSESSMENT; FATTY LIVER; FIBROGENESIS; GOLD STANDARD; HISTOPATHOLOGY; HUMAN; ISOTOPE LABELING; LIVER BIOPSY; LIVER CLEARANCE; LIVER CYTOSOL; LIVER FIBROSIS; LIVER FUNCTION TEST; LIVER MICROSOME; LIVER MITOCHONDRION; LONGITUDINAL STUDY; MEASUREMENT REPEATABILITY; NONALCOHOLIC FATTY LIVER; PATIENT IDENTIFICATION; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; NON-ALCOHOLIC FATTY LIVER DISEASE; PROCEDURES; SEVERITY OF ILLNESS INDEX;

BREATH TESTS; HUMANS; NON-ALCOHOLIC FATTY LIVER DISEASE; SEVERITY OF ILLNESS INDEX;

EID: 84922326013     PISSN: 15748871     EISSN: 18761038     Source Type: Journal    
DOI: 10.2174/1574887109666141216104917     Document Type: Article

References (58)

1. [1] Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 2006; 43: S99-112.
2. [2] Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002; 346: 1221-31.
3. [3] Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 2011; 34: 274-85.
4. [4] Wong RJ, Cheung R, Ahmed A. Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the U.S. Hepatology 2014; 59: 2188-95.
5. [5] Jimba S, Nakagami T, Takahashi M, Wakamatsu T, Hirota Y, Iwamoto Y, Wasada T. Prevalence of non-alcoholic fatty liver disease and its association with impaired glucose metabolism in Japanese adults. Diabet Med 2005; 22: 1141-5.
6. [6] Sanyal AJ, Campbell-Sargent C, Mirshahi F, Rizzo WB, Contos MJ, Sterling RK Luketic VA, Shiffman ML, Clore JN. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001; 120: 1183-92.
7. [7] Kotronen A, Westerbacka J, Bergholm R, Pietilainen KH, Yki-Jarvinen H. Liver fat in the metabolic syndrome. J Clin Endocrinol Metab 2007; 92: 3490-7.
8. [8] Cadranel JF, Rufat P, Degos F. Practices of liver biopsy in France: results of a prospective nationwide survey. For the group of epidemiology of the french association for the study of the liver (AFEF). Hepatology 2000; 32: 477-81.
9. [9] Rockey DC, Caldwell SH, Goodman ZD, Nelson RC, Smith AD. American association for the study of liver disease. Liver biopsy. Hepatology 2009; 49: 1017-44.
10. [10] Bedossa P, Dargere D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 2003; 38: 1449-57.
11. [11] Poynard T, Munteanu M, Imbert-Bismut F, Charlotte F, Thabut D, Le Calvez S, Messous D, Thibault V, Benhamou Y, Moussalli J, Ratziu V. Prospective analysis of discordant results between biochemical markers and biopsy in patients with chronic hepatitis C. Clin Chem 2004; 50: 1344-55.
12. [12] Barstow L, Small RE. Liver function assessment by drug metabolism. Pharmacotherapy 1990; 10: 280-8.
13. [13] Reichen J. Assessment of hepatic function with xenobiotics. Semin Liver Dis 1995; 15: 189-201.
14. [14] Armuzzi A, Candelli M, Zocco MA, Andreoli A, De Lorenzo A, Nista EC, Miele L, Cremonini F, Cazzato IA, Grieco A, Gasbarrini G, Gasbarrini A. Review article: breath testing for human liver function assessment. Aliment Pharmacol Ther 2002; 16: 1977-96.
15. [15] Brockmöller J, Roots I. Assessment of liver metabolic function. Clin Pharmacokinet 1994; 27: 216-48.
16. [16] Giannini EG, Testa R. 13C-breath tests and liver fibrosis. Eur Rev Med Pharmacol Sci 2004; 8: 51-4.
17. [17] Van der Weide J, Steijns LS. Cytochrome P450 enzyme system: genetic polymorphisms and impact on clinical pharmacology. Ann Clin Biochem 1999; 36: 722-9.
18. [18] Niwa T, Sato R, Yabusaki Y, Ishibashi F, Katagiri M. Contribution of human hepatic cytochrome P450s and steroidogenic CYP17 to the N-demethyliation of aminopirine. Xenobiotica 1999; 29: 187-93.
19. [19] Monroe PS, Baker AL, Schneider JF, Krager PS, Klein PD, Schoeller D. The aminopyrine breath test and serum bile acids reflect histologic severity in chronic hepatitis. Hepatology 1982; 3: 317-22.
20. [20] Schoeller D, Baker AL, Monroe PS, Krager PS, Schneider JF. Comparison of different methods of expressing results of the aminopyrine breath test. Hepatology 1982; 4: 455-62.
21. [21] Giannini E, Fasoli A, Chiarbonello B, Malfatti F, Romagnoli P, Botta F, Testa E, Polegato S, Fumagalli A, Testa R. 13Caminopyrine breath test to evaluate severity of disease in patients with chronic hepatitis C virus infection. Aliment Pharmacol Ther 2002; 16: 717-25.
22. [22] Giannini EG, Fasoli A, Borro P, Botta F, Malfatti F, Fumagalli A, Testa E, Polegato S, Cotellessa T, Milazzo S, Risso D, Testa R. 13C-galactose breath test and 13C-aminopyrine breath test for the study of liver function in chronic liver disease. Clin Gastroenterol Hepatol 2005; 3: 279-85.
23. [23] Giannini EG, Savarino V. Relationship between 13C-aminopyrine breath test and the MELD score and its long-term prognostic use in patients with cirrhosis. Dig Dis Sci 2013; 58: 3024-8.
24. [24] Ecochard M, Boillot O, Guillaud O, Roman S, Adham M, Mion F, Dumortier J. Could metabolic liver function tests predict mortality on waiting list for liver transplantation? A study on 560 patients. Clin Transplant 2011; 25: 755-65.
25. [25] Schneider JF, Schoeller DA, Schreider BD, Kotake AN, Hachey DL, Klein PD. Use of 13C-phenacetin and 13C-methacetin for the detection of alterations in hepatic drug metabolism. In: Klein ER, Klein PD, eds. Stable Isotopes: Proceedings of the Third International Conference. New York: Academic Press. 1979: 507-16.
26. [26] Klatt S, Taut C, Mayer D, Adler G, Beckh K. Evaluation of the 13C-methacetin breath test for quantitative liver function testing. Z Gastroenterol 1997; 35: 609-14.
27. [27] Ciccocioppo R, Candelli M, Di Francesco D, Ciocca F, Taglieri G, Armuzzi A, Gasbarrini G, Gasbarrini A. Study of liver function in healthy elderly subjects using the 13C-methacetin breath test. Aliment Pharmacol Ther 2003; 17: 271-7.
28. [28] Renner E, Wietholtz H, Huguenin P, Arnaud MJ, Preisig R. Caffeine: a model compound for measuring liver function. Hepatology 1984; 4: 38-46.
29. [29] Schmilovitz-Weiss H, Niv Y, Pappo O, Halpern M, Sulkes J, Braun M, Barak N, Rotman Y, Cohen M, Waked A, Tur-Kaspa R, BenAri Z. The 13C-Caffeine breath test detects significant fibrosis in patients with nonalcoholic steatohepatitis. J Clin Gastroenterol 2008; 42: 408-12.
30. [30] Park GJH, Wiseman E, George J, Katelaris PH, Seow F, Fung C, Ngu MC. Non-invasive estimation of liver fibrosis in non-alcoholic fatty liver disease using the 13C-Caffeine breath test. J Gastroenterol Hepatol 2011; 26: 1411-6.
31. [31] Shreeve WW, Shoop JD, Ott DG, McInteer BB. Test for alcoholic cirrhosis by conversion of [14C] or [13C] galactose to expired CO2. Gastroenterology 1976; 72: 98-101.
32. [32] Caspary WF, Shaffer J. 14C-d-galactose breath test for evaluation of liver function in patients with chronic liver disease. Digestion 1978; 17: 410-8.
33. [33] Giannini EG, Testa R. Non-invasive assessment of liver function: trying not to miss an opportunity. Aliment Pharmacol Ther 2004; 19: 827-8.
34. [34] Burke PA, Stack JA, Wagner D, Lewis DW, Jenkins RL, Forse RA. l-[1-13C] phenylalanine oxidation as a measure of hepatocyte functional capacity in end-stage liver disease. Am J Surg 1997; 173: 270-4.
35. [35] Kobayashi T, Kubota K, Imamura H, Hasegawa K, Inoue Y, Takayama T, Makuuchi M. Hepatic phenylalanine metabolism measured by the [13C]phenylalanine breath test. Eur J Clin Invest 2001; 31: 356-61.
36. [36] Lara Baruque S, Razquin M, Jimenez I, Vazquez A, Gisbert JP, Pajares JM. 13C-phenylalanine and 13C-methacetin breath test to evaluate functional capacity of hepatocyte in chronic liver disease. Dig Liver Dis 2000; 32: 226-32.
37. [37] Giannini E, Fasoli A, Botta F, Romagnoli P, Malfatti F, Chiarbonello B, Testa R. Is there a role for multiple quantitative liver function tests? Dig Liver Dis 2000; 32: 644.
38. [38] Begriche K, Igoudjil A, Pessayre D, fromenty B. Mitochondrial dysfunction in NASH: causes, consequences and possible means to prevent it. Mitochondrion 2006; 6: 1-28.
39. [39] Lauterburg BH, Liang D, Schwarzenbach FA, Breen KJ. Mitochondrial dysfunction in alcoholic patients as assessed by breath analysis. Hepatology 1993; 17: 418-22.
40. [40] Lauterburg BH, Grattagliano I, Gmur R, Stalder M, Hildebrand P. Noninvasive assessment of the effect of xenobiotics on mitochondrial function in human beings: studies with acetylsalicylic acid and ethanol with the use of the carbon 13-labeled ketoisocaproate breath test. J Lab Clin Med 1995; 125: 378-83.
41. [41] Honkoop P, De Man RA, Scholte HR, Zondervan PE, Van Den Berg JW, Rademakers LH, Schalm SW. Effect of lamivudine on morphology and function of mitochondria in patients with chronic hepatitis B. Hepatology 1997; 26: 211-5.
42. [42] Armuzzi A, Marcoccia S, Zocco MA, De Lorenzo A, Grieco A, Tondi P, Pola P, Gasbarrini G, Gasbarrini A. Non-invasive assessment of human hepatic mitochondrial function through the 13Cmethionine breath test. Scand J Gastroenterol 2000; 35: 650-3.
43. [43] Banasch M, Ellrichmann M, Tannapfel A, Schmidt WE, Goetze O. The non-invasive 13C-methionine breath test detects hepatic mitochondrial dysfunction as a marker of disease activity in nonalcoholic steatohepatitis. Eur J Med Res 2011; 16: 258-64.
44. [44] Woolf GM, Wagner DA, Cohen SM, Vierling JM. A breath test to determine hepatic mitochondrial function. Hepatology 1997; 26: 271A.
45. [45] Portincasa P, Grattagliano I, Lauterburg BH, Palmieri VO, Palasciano G, Stellaard F. Liver breath tests non-invasively predict higher stages of non-alcoholic steatohepatitis. Clin Sci 2006; 111: 135-43.
46. [46] Fierbinteanu-Braticevici C, Plesca DA, Tribus L, Panaitescu E, Braticevici B. The role of 13C-methacetin breath test for the noninvasive evaluation of non-alcoholic fatty liver disease. J Gastrointestin Liver Dis 2013; 22: 149-56.
47. [47] Park GJ, Katelaris PH, Jones DB, Seow F, Lin B P, Le Couteur DG, Ngu MC. The C-caffeine breath test distinguishes significant fibrosis in chronic hepatitis B and reflects response to lamivudine therapy. Aliment Pharmacol Ther 2005; 22: 395-403.
48. [48] Schmilovitz-Weiss H, Niv Y, Pappo O, et al. The 13C-Caffeine breath test detects signficant fibrosis in patients with nonalcoholic steatohepatitis. J Clin Gastroenterol 2008; 42: 408-12.
49. [49] Castéra L, Foucher J, Bernard PH, et al. Pitfalls of liver stiffness measurement: a 5-year prospective study of 13 369 examinations. Hepatology 2010; 51: 828-35.
50. [50] De Lédinghen V, Vergniol J, Foucher J, El-Hajbi F, Merrouche W, Rigalleau V. Feasibility of liver transient elastography with Fibroscan using a new probe for obese patients. Liver Int 2010; 30: 1043-8.
51. [51] Miele L, Grieco A, Armuzzi A, et al. Hepatic mitochondrial betaoxidation in patients with nonalcoholic steatohepatitis assessed by 13c-octanoate breath test. Am J Gastroenterol 2003; 98: 2335-6.
52. [52] Mawatari H, Inamori M, Fujita K, et al. The continuous real-time 13C-octanoate breath test for patients with nonalcoholic steatohepatitis using the Breath ID system. Hepatogastroenterology 2009; 56: 1436-8.
53. [53] Tribonias G, Margariti E, Tiniakos D, Pectasides D, Papathodoridis GV. Liver function breath tests for differentiation of steatohepatitis from simple fatty liver in patients with nonalcoholic fatty liver disease. J Clin Gastroenterol 2014; 48: 59-65.
54. [54] Tarantino G, Conca P, Capone D, Gentile A, Polichetti G, Basile V. Reliability of total overnight salivary caffeine assessment (TOSCA) for liver function evaluation in compensated cirrhotic patients. Eur J Clin Pharmacol 2006; 62: 605-12.
55. [55] Tarantino G, Conca P, Pasanisi F, et al. Could inflammatory markers help diagnose nonalcoholic steatohepatitis? Eur J Gastroenterol Hepatol 2009; 21: 504-11.
56. [56] Tarantino G. Could quantitative liver function tests gain wide acceptance among hepatologists? World J Gastroenterol 2009; 15: 3457-61.
57. [57] Angulo P, Hui JM, Marchesini G, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 2007; 45: 846-54.
58. [58] Guha IN, Parkes J, Roderick P, et al. Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: validating the European Liver. Fibrosis Panel and exploring simple markers. Hepatology 2008; 47: 455-60.